Market Overview

Ossianix and Novo Nordisk Sign Research and Option Agreement on Blood Brain Barrier Delivery Technology for Proteins in Diabetes and Other Metabolic Diseases

Share:

Ossianix, Inc. today announced a research collaboration and option
agreement with Novo Nordisk to deliver therapeutic molecules in diabetes
and other metabolic diseases across the Blood Brain Barrier (BBB) to the
brain.

Under the terms of the agreement, Ossianix will use its patented single
domain VNAR antibodies to deliver a predefined number of therapeutic
agents of Novo Nordisk. Novo Nordisk will be responsible for the
development and commercialization of the therapeutic products.

Ossianix will receive upfront, pre-clinical, clinical and commercial
milestone payments, R&D funding, as well as product royalties from Novo
Nordisk. In addition, Novo Nordisk has a buyout option for each product
on pre-agreed financial terms.

Financial details of the agreement are not being disclosed.

Dr. Frank Walsh, CEO of Ossianix, stated: "We are very excited to be
working with Novo Nordisk, a global healthcare company with 95 years of
innovation and leadership in diabetes care. Ossianix's single domain
VNAR antibodies BBB platform is capable of delivering high levels of
therapeutic products to the central nervous system utilizing the
transferrin receptor. We look forward to developing a successful
collaborative relationship with Novo Nordisk on drug targets in the CNS
associated with diabetes and metabolic disease which are areas of huge
medical need."

"We are excited about the opportunity to collaborate with Ossianix, who
has developed a unique platform for delivery of proteins and peptides to
the brain using their proprietary blood-brain-barrier shuttle
technology. In combination with our experience in disease biology, the
projects that we will collaborate on hold potential to make a real
difference for people living with diabetes and other metabolic
diseases," said Dr. Marcus Schindler, Senior Vice President, Global Drug
Discovery at Novo Nordisk.

About Ossianix

Ossianix is a privately held research company based in Philadelphia, PA
with research laboratories in the UK. It develops novel
biopharmaceuticals for a number of therapeutic areas including CNS.

Ossianix's patented single domain VNAR antibody synthetic phage
libraries have been used to isolate BBB translocating modules to
endogenous transport systems such as the transferrin receptor. This so
called "Trojan Horse" approach has favorable characteristics including
the ability to deliver biologics to the brain parenchyma at therapeutic
doses with excellent long lasting pharmacokinetic properties.

The company utilizes this versatile single domain shark VNAR scaffold to
engineer unique differentiated products in a variety of therapeutic
formats for different types of Biologics. Its lead product is a brain
penetrant CD20 antibody for multiple sclerosis and cerebral lymphoma.

The company was founded by former senior executives from Wyeth and
Pfizer, Drs. Frank S. Walsh, Corey S. Goodman and J. Lynn Rutkowski.

For more information please visit www.ossianix.com.

View Comments and Join the Discussion!